New Players in the treatment of Community-Acquired Pneumonia (CAP): Ceftaroline and Corticosteroids by Steven P. LaRosa, M.D.
The treatment of community-acquired pneumonia (CAP) has been for many years unchanged and boring. We give a macrolide to cover Legionella, Chlamydophila, and Mycoplasma and Ceftriaxone, a 3 rd generation Cephalosporin, to cover the dreaded Pneumococcus and Haemophilus influenzae . Data from recent clinical trials would suggest a role for Ceftaroline and corticosteroids. Ceftaroline Ceftaroline, a “5 th Generation Cephalosporin” has a similar spectrum of action as the CAP workhouse drug Ceftriaxone but also has activity against MRSA. There have now been 3 Phase III trials of Ceftaroline vs. Ceftriaxone in CAP patients with a moderate severity of illness as indicated by PORT scores III and IV. The primary efficacy variable was clinical response at days 8-15 in the modified intent to treat population (patients who were randomized and received some study drug). In a meta-analysis (Antimicrob Chemother 2016; 71: 862–870), A superior clinical response was observed with Ceftaroli...